Stockscreener 앱 받기
11.17
2.57%
0.28
시간 외 거래:
11.15
-0.02
-0.18%
Arvinas Inc 주식(ARVN)의 최신 뉴스
Arvinas (ARVN) CMO reports automatic RSU tax-withholding share sale - Stock Titan
Arvinas (ARVN): Citigroup Raises Price Target to $21.00 and Main - GuruFocus
Arvinas (NASDAQ:ARVN) Price Target Raised to $21.00 at Citigroup - MarketBeat
Arvinas (NASDAQ:ARVN) Stock Price Expected to Rise, BTIG Research Analyst Says - MarketBeat
BTIG Analyst Raises Price Target for Arvinas (ARVN) to $16 | ARV - GuruFocus
Arvinas reports positive Phase 1 data for Parkinson’s drug ARV-102 By Investing.com - Investing.com South Africa
Arvinas reports positive Phase 1 data for Parkinson’s drug ARV-102 - Investing.com India
Arvinas, Inc. (ARVN) reports Q4 loss, misses revenue estimates - MSN
BTIG raises Arvinas stock price target on positive trial data - Investing.com
ARV-102 Data Strengthens Neurodegeneration Pipeline Prospects, Supporting Higher $16 Target and Buy Rating on Arvinas - TipRanks
Arvinas (ARVN) Reports Promising Phase 1 Trial Results for ARV-102 in Parkinson's Disease - GuruFocus
Truist reiterates Hold on Arvinas stock after Parkinson’s trial data By Investing.com - Investing.com Australia
Arvinas, Inc. Reports Forward-Looking Statements and Updates on ARV-102 Neurodegenerative Disease Program – March 2026 - Minichart
Truist reiterates Hold on Arvinas stock after Parkinson’s trial data - Investing.com
Arvinas (NASDAQ:ARVN) Trading Down 7.8%What's Next? - MarketBeat
Arvinas Reports Positive Phase 1 Data for ARV-102 - TipRanks
Arvinas (ARVN) reports positive Phase 1 ARV-102 data in Parkinson’s disease - Stock Titan
Arvinas Announces Positive Phase 1 Data for ARV-102 Showing - GlobeNewswire
Arvinas (ARVN) settles 6,022 RSUs; insider sold 5,685 shares - Stock Titan
ARVN SEC FilingsArvinas 10-K, 10-Q, 8-K Forms - Stock Titan
ARVN Should I Buy - Intellectia AI
Arvinas calls for new approaches in neurodegenerative disease research - Traders Union
Goldman Sachs Downgrades Arvinas (ARVN) - MSN
Investor Mood: Can Arvinas Inc outperform in the next rally2026 Weekly Recap & Long-Term Safe Return Strategies - baoquankhu1.vn
Arvinas, Inc. (ARVN) Reports Q2 Loss, Misses Revenue Estimates - MSN
Arvinas (ARVN) corrects CEO equity grant to 147,179 RSUs in Form 4/A - Stock Titan
Arvinas (NASDAQ:ARVN) Shares Down 7.8%What's Next? - MarketBeat
Arvinas to present ARV-102 Parkinson’s trial data at conference By Investing.com - Investing.com South Africa
Arvinas, Inc. (NASDAQ:ARVN) Q4 2025 earnings call transcript - MSN
Arvinas to Present Phase 1 Data for ARV-102, a PROTAC LRRK2 Degrader, in Oral Session at the 2026 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders - The Manila Times
Arvinas, Inc. to Present Phase 1 Trial Data on ARV-102 for Parkinson’s Disease at AD/PD 2026 Conference - Quiver Quantitative
Arvinas to present ARV-102 Parkinson’s trial data at conference - Investing.com
Early ARV-102 Parkinson’s data to debut at Alzheimer’s-Parkinson’s conference - Stock Titan
Arvinas Highlights Phase 1 Shift, 2026 Data Catalysts, and Vepdegestrant NDA at Barclays Conference - MarketBeat
Arvinas to Present Phase 1 Data for ARV-102, a PROTAC LRRK2 Degrader, in Oral Session at the 2026 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders - Bitget
Arvinas (NASDAQ:ARVN) Sets New 12-Month High on Insider Buying Activity - MarketBeat
Arvinas Stock Pre-Market (+4.7%): Broad Biotech Rally on Geopolitical De-escalation, Falling Oil - Trefis
Arvinas Teases Near-Term Phase 1 Data, Eyes New Vepdegestrant Partner at Leerink Conference - MarketBeat
Insider Buying: Briggs Morrison Acquires 20,000 Shares of Arvinas Inc (ARVN) - GuruFocus
ARVN: Multiple phase I programs advance, with key data for LRRK2 and KRAS G12D degraders expected in 2024 - TradingView
Briggs Morrison Acquires 20,000 Shares of Arvinas (NASDAQ:ARVN) Stock - MarketBeat
Vanguard Group Inc. Trims Position in Arvinas, Inc. $ARVN - MarketBeat
Institution Moves: What dividend growth rate does Arvinas Inc offer2025 Macro Impact & Weekly Breakout Opportunity Watchlist - baoquankhu1.vn
Why analysts remain bullish on Arvinas Inc. stock2025 Trading Recap & Accurate Buy Signal Alerts - Naître et grandir
Piper Sandler reiterates Arvinas stock rating on platform validation By Investing.com - Investing.com India
Piper Sandler reiterates Arvinas stock rating on platform validation - Investing.com South Africa
How The Arvinas (ARVN) Narrative Is Evolving With New Leadership And Key 2026 Pipeline Catalysts - Yahoo Finance
Discipline and Rules-Based Execution in ARVN Response - Stock Traders Daily
Arvinas (NASDAQ:ARVN) Given New $18.00 Price Target at Citigroup - MarketBeat
Citigroup Raises Price Target for Arvinas (ARVN) to $18.00 | ARV - GuruFocus
ARVN Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Arbiter Partners Capital Management LLC Invests $3.86 Million in Arvinas, Inc. $ARVN - MarketBeat
Arvinas Highlights Growing Phase 1 Pipeline, Near-Term Catalysts at TD Cowen Healthcare Conference - MarketBeat
ARVN: Multiple phase I programs advance with key data and commercialization milestones ahead - TradingView
ARVN: Multiple phase 1 programs advance with key data updates expected for LRRK2, BCL6, and KRAS - TradingView
Arvinas (NASDAQ:ARVN) Director John Houston Sells 35,297 Shares - MarketBeat
Arvinas (NASDAQ: ARVN) CEO receives large stock option and RSU grants - Stock Titan
Arvinas (ARVN) grants CMO 67,000 options and 45,000 RSUs - Stock Titan
Arvinas (ARVN) CSO awarded 67,000 options and 45,000 RSUs - Stock Titan
1.20%
0.06%
자본화:
|
볼륨(24시간):